Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07810972) titled 'Evaluate the Safety and Efficacy of TJO-087' on Sept. 2.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Taejoon Pharmaceutical Co., Ltd.

Condition: Dry Eye Syndrome (DES)

Intervention: Drug: TJO-087 Drug: TJO-087

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: April 6, 2026

Target Sample Size: 90

Countries of Recruitment: South Korea

To know more, visit https://clinicaltrials.gov/study/NCT0...